Compare AbbVie Inc (ABBV) vs Wipro Limited (WIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Wipro Limited — how do they compare? AbbVie Inc trades at $254.08 (market cap $449.91B), while Wipro Limited trades at $1.84 (market cap $18.14B). The key difference: AbbVie Inc is far larger — about 24.8× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (10.37%). Which is the better fit depends on your goals.
| ABBV | WIT | |
|---|---|---|
Market Cap | $449.91B | $18.14B |
Sector | Health | Technology |
52-Week High | $261.07 | $3.09 |
52-Week Low | $184.85 | $1.82 |
Enterprise Value | $513.38B | $14.53B |
Dividend Yield | 2.72% | 10.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
WIT trades at $1.85, down 2.12% today, with a bearish technical signal from moving averages. The company reported revenue of $890.88B in 2025 with a net income margin of 14.25% and a P/E ratio of 13.82. Recent earnings have missed estimates for three consecutive quarters, and analyst sentiment is mixed with a Hold consensus. News highlights include AI partnerships and a weak Q2 2026 revenue outlook.
The outlook is cautious due to near-term revenue pressure and earnings misses, though valuation appears reasonable. Risks include client spending caution and competitive pressures. Upside may depend on AI-driven growth initiatives and large deal execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
